Narrative review details GH-IGF-1 axis modulating peptides, exposing risks and evidence gaps in self-administration.
Background
The growth hormone-insulin-like growth factor-1 (GH-IGF-1) axis is a key target for individuals seeking performance enhancement or body recomposition. However, an unregulated market has emerged, offering various peptides marketed as "research compounds" that modulate this axis. These compounds lack regulatory approval for physique- or performance-related indications, leading to significant uncertainty regarding their composition, dosing, and safety. Clinicians face a growing challenge in interpreting symptoms and laboratory abnormalities in patients self-administering these substances, necessitating a clear framework to bridge the gap between clinical evidence and common self-administration practices.
Study Design
This narrative review systematically contrasted peer-reviewed pharmacokinetic/pharmacodynamic and clinical evidence with commonly encountered online self-administration protocols for GH-IGF-1 axis modulating peptides. The authors stratified peptides into evidence tiers, ranging from regulatory-grade randomized trial data to a complete absence of human studies. They summarized structural characteristics, pharmacologic effects, and commonly reported dosing patterns. The review synthesized clinically relevant adverse effects, with particular attention to hormonal imbalance, endocrine-metabolic risk, and product composition uncertainty, to provide a pragmatic framework for clinicians.
Results
The review identified several classes of GH-IGF-1 axis modulating peptides commonly encountered in clinical practice and online self-administration. These include growth hormone-releasing hormone (GHRH) analogues (e.g., sermorelin, tesamorelin, CJC-1295 with DAC, CJC-1295 without DAC), growth hormone secretagogues (GHS) (e.g., GHRP-2, GHRP-6, hexarelin, ipamorelin), the growth hormone (GH) fragment - AOD9604 (hGH 176-191), and insulin-like growth factor-1 (IGF-1) analogues (e.g., pegylated mechano growth factor (PEG-MGF), IGF-1 Long R3 (IGF-1 LR3)). Reported adverse effects were extensive, spanning endocrine and metabolic disturbances (including prolactin and cortisol elevations, appetite changes, and dysglycaemia), fluid retention syndromes, musculoskeletal symptoms (myalgia/arthralgia), and injection-site reactions. The review highlighted significant uncertainty surrounding product composition, dose, and stacking practices in unregulated supply chains.
The primary finding emphasizes a critical disconnect between the limited, often contradictory, clinical evidence and the widespread, unvalidated self-administration protocols, leading to substantial health risks.
Key Findings
- Unregulated GH-IGF-1 axis modulating peptides are widely self-administered for performance enhancement.
- Commonly used peptides include GHRH analogues (sermorelin, CJC-1295), GHS (ipamorelin, GHRP-2), AOD9604, and IGF-1 analogues (PEG-MGF).
- Reported adverse effects include endocrine/metabolic disturbances (prolactin/cortisol elevation, dysglycaemia), fluid retention, and musculoskeletal pain.
- Significant uncertainty exists regarding product composition, dose, and stacking practices in unregulated supply chains.
- Clinical evidence often contradicts or is absent for commonly encountered online self-administration protocols.
Why It Matters
For peptide users and biohackers, this review underscores the profound risks associated with self-administering unregulated GH-IGF-1 axis modulating peptides. The lack of validated protocols, coupled with unknown product purity and potency, means that any perceived performance or recomposition benefits come with significant, often unquantified, health hazards. Clinicians now have a pragmatic framework to interpret symptoms and laboratory abnormalities in patients using these compounds, enabling better risk assessment and patient counseling. This work highlights that current online self-administration protocols are largely unsupported by robust clinical evidence, making it crucial to prioritize safety and regulatory oversight over anecdotal claims. Users should exercise extreme caution, as the potential for hormonal imbalance and severe metabolic disturbances is high.
gh-igf-1-axis
peptides
performance-enhancement
sermorelin
ipamorelin
cjc-1295